[Stemline Therapeutics, Inc. letterhead]
VIA EDGAR AND
OVERNIGHT DELIVERY
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, DC 20549
Re: |
Stemline Therapeutics, Inc. / Application For Withdrawal on Form RW for Registration Statement on Form S-1 (File No. 333-191782) (the Registration Statement) |
Ladies and Gentlemen:
Pursuant to Rule 477 under the Securities Act of 1933, as amended (the Act), Stemline Therapeutics, Inc. (the Company) hereby applies for the withdrawal of the Registration Statement and requests that the Securities and Exchange Commission (the Commission) consent thereto. No securities have been issued or sold under the Registration Statement. The Registration Statement has not been declared effective by the Commission. The Company submits this request for withdrawal as it does not intend to pursue the contemplated public offering at this time.
If you have any questions regarding this letter, please contact the Companys legal counsel, Matthew W. Mamak, Esq., of Alston & Bird LLP, at (212) 210-1256.
|
Sincerely, | |
|
| |
|
STEMLINE THERAPEUTICS, INC. | |
|
| |
|
| |
|
By: |
/s/ Kenneth Hoberman |
|
|
Kenneth Hoberman |
|
|
Chief Operating Officer |
cc: Dr. Ivan Bergstein (Chief Executive Officer, Stemline Therapeutics, Inc.)
Mark F. McElreath, Esq. (Alston & Bird LLP)
Jonathan L. Kravetz, Esq. (Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.)
Ivan K. Blumenthal, Esq. (Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.)
Scott A. Samuels, Esq. (Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.)